Endogenous fibrinolytic potential in tissue-plasminogen activator-modified thromboelastography analysis is significantly decreased in dogs suffering from diseases predisposing to thrombosis by Spodsberg, Eva-Maria Hohneck et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Endogenous fibrinolytic potential in tissue-plasminogen activator-modified
thromboelastography analysis is significantly decreased in dogs suffering from
diseases predisposing to thrombosis
Spodsberg, Eva-Maria Hohneck;  Wiinberg, Bo; Jessen, Lisbeth Rem; Marschner, Clara
Büchner; Kristensen, Annemarie Thuri
Published in:
Veterinary Clinical Pathology
DOI:
10.1111/vcp.12068
Publication date:
2013
Document version
Early version, also known as pre-print
Citation for published version (APA):
Spodsberg, E-M. H., Wiinberg, B., Jessen, L. R., Marschner, C. B., & Kristensen, A. T. (2013). Endogenous
fibrinolytic potential in tissue-plasminogen activator-modified thromboelastography analysis is significantly
decreased in dogs suffering from diseases predisposing to thrombosis. Veterinary Clinical Pathology, 42(3), 281-
290. https://doi.org/10.1111/vcp.12068
Download date: 02. Feb. 2020
O R I G I N A L R E S E A R C H
Endogenous fibrinolytic potential in tissue-plasminogen
activator-modified thromboelastography analysis is
significantly decreased in dogs suffering fromdiseases
predisposing to thrombosis
Eva H. Spodsberg1, BoWiinberg2, Lisbeth R. Jessen1, Clara B. Marschner1, Annemarie T. Kristensen1
1Department of Clinical Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University Hospital for Companion Animals, University
of Copenhagen, Frederiksberg C, Denmark; and 2Biopharmaceuticals Research Unit, Novo Nordisk A/S, Maløv, Denmark
KeyWords
Canine, fibrinolysis, kaolin-activated TEG,
native TEG, tissue-factor (TF)-activated TEG
Correspondence
Dr. Eva H. Spodsberg, University Hospital
for Companion Animals, Department of
Veterinary Clinical and Animal Sciences,
Faculty of Health and Medical Sciences,
University of Copenhagen, Dyrlægevej 16,
Frederiksberg C 1870, Denmark
E-mail: Evahs@sund.ku.dk
DOI:10.1111/vcp.12068
Background: In people, studies have shown that resistance to fibrinolysis
could be a contributing factor to thrombosis. Tissue-plasminogen-activated
(t-PA) thromboelastography (TEG) has been used to evaluate endogenous
fibrinolytic potential. In dogs, TEG has been used for the diagnosis of vari-
ous hemostatic disorders, but studies evaluating fibrinolysis are limited.
Investigations into the potential of t-PA-modified TEG to monitor endoge-
nous fibrinolytic potential are lacking in both healthy dogs and dogs with
diseases predisposing to development of thrombosis.
Objectives: The aim of this study was to compare 3 t-PA-modified TEG
assays and compare the endogenous fibrinolytic potential in dogs suffering
from diseases associated with thrombosis with a group of healthy dogs.
Methods: Three different TEGassays, such as native, tissue factor-activated,
and kaolin-activated, were modified with t-PA and used to compare whole
blood samples from16 healthy control dogs and 20 diseased dogs.
Results: Thromboelastography lysis variables were significantly affected
by addition of t-PA in all 3 assays. Lysis results in diseased dogs were com-
parable to those in healthy dogs prior to addition of t-PA. After addition of
t-PA, lysis results were significantly decreased in the diseased group com-
pared with healthy dogs. The lowest median lysis levels were found in dogs
with systemic inflammation and protein-losing disorders.
Conclusion: Addition of t-PA activates fibrinolysis in TEG of blood from
both healthy dogs and dogs with diseases predisposing to thrombosis. The
significantly decreased fibrinolysis in diseased dogs suggests that this may
be a potential prothrombotic risk factor in dogs.
Introduction
Fibrinolysis is an essential part of the hemostatic pro-
cess protecting against permanent thrombotic occlu-
sion of damaged vessels in which a clot has formed.
The balance between coagulation and fibrinolysis
determines the size, quality, rate of dissolution, and life
span of the clot.1,2 A balanced and healthy fibrinolytic
mechanism dissolves the occlusive thrombus before
permanent tissue damage occurs.1 Fibrinolysis is initi-
ated when plasminogen is converted to plasmin by one
of several plasminogen activators, with tissue plasmin-
ogen activator (t-PA) as the main intravascular activa-
tor.2 Plasmin mediates degradation of fibrinogen or
soluble fibrin resulting in the formation of fibrin or
fibrinogen degradation products (FDPs). Plasmin also
mediates degradation of cross-linked, insoluble fibrin
to produce D-dimers. As D-dimers result only from the
degradation of cross-linked fibrin in a stabilized clot,
they are, in contrast to other degradation products,
specific for active coagulation and fibrinolysis.3 Both
the FDP and D-dimer assays are plasma-based and the
only tests routinely used to evaluate fibrinolysis in
dogs.
In human medicine, D-dimer tests are useful for
the clinical diagnosis of patients suspected of having
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deep-vein thrombosis (DVT) and patients with pulmo-
nary thromboembolism (PTE).4–6 In patients with a
low or moderate pretest probability of disease, a nega-
tive D-dimer test result helps in ruling out venous
thromboembolism.7 In veterinary medicine, D-dimer
tests have been used in the diagnosis of canine throm-
boembolic diseases, mainly PTE, with a negative test
being considered a strong indicator of the absence of
thromboembolism.3,8
Several disease conditions have been associated
with the development of thrombosis in dogs.9 These
include immune-mediated hemolytic anemia (IMHA),10
protein-losing conditions,11–13 hyperadrenocorticism,14
neoplasias,15,16 parvovirus infection,17 sepsis,18 early dis-
seminated intravascular coagulation (DIC),19 and con-
gestive heart failure.20 The current understanding and
ability to diagnose and monitor thrombotic disease
including fibrinolysis are limited. Specifically, defects of
the fibrinolytic system or resistance to fibrinolysis have
not been investigated, as no standardized tests are avail-
able to measure the global endogenous fibrinolytic
potential of whole blood and determined risk factors for
thromboembolic disease in dogs. In people, plasminogen-
activator-induced fibrinolysis has been evaluated by
thromboelastography (TEG) in several studies.21–27
Fibrinolysis has recently been standardized by using
t-PA-induced, tissue-factor (TF)-activated TEG in
human samples, and has been reported to provide rapid
assessment of the endogenous fibrinolytic potential of
whole blood.21 In another study with t-PA-modified
TEG performed on whole blood from children with non-
catheter-related DVT, the authors concluded that
decreased fibrinolytic activity likely is a contributing fac-
tor to thrombosis.22 TEG is increasingly used in the diag-
nosis and monitoring of hemostatic disorders in dogs,28
including both hypercoagulable10–20 and fibrinolytic
disorders.25,26,29–31 Recently, TEG was used to measure
TF-initiated fibrin formation and t-PA-induced fibrinoly-
sis in human and canine hemophilic blood after addition
of the anti-fibrinolytic Solulin, a soluble analog of throm-
bomodulin with anti-fibrinolytic properties used to
increase clot lysis time.25 Blood obtained fromhemophil-
ic dogs given Solulin intravenously was found to
generate clots that are resistant to fibrinolysis.
Studies assessing the ability of t-PA-modified TEG
to evaluate fibrinolytic potential in healthy dogs and
dogs with diseases known to predispose to thrombosis
have not been reported. Early identification of dogs
with altered fibrinolytic activity could ultimately help
direct therapeutic measures or predict outcome. There-
fore, our main hypothesis was that the addition of t-PA
to TEG would activate fibrinolysis in canine whole
blood from healthy dogs and dogs with diseases
associated with development of thrombosis. In addi-
tion, we hypothesized that the fibrinolytic activity
would be decreased in dogs with diseases associated
with thrombosis when compared with healthy dogs.
For that purpose, 3 different t-PA-modified TEG assays
were compared.
Materials andMethods
The study was performed as a prospective, ex vivo
study between January 2010 and March 2011 at the
University Hospital for Companion Animals, Depart-
ment of Veterinary Clinical and Animal Sciences
(UHCA-DVCAS), Faculty of Health and Medical Sci-
ences, University of Copenhagen, Denmark. The study
was approved by the Ethics and Administrative Com-
mittee. All laboratory analyses were performed at The
Central Laboratory, DVCAS. Forty dogs were included
in this study, with a control group consisting of 20
healthy dogs and a group of 20 dogs with diseases
potentially associated with thrombosis.
Animals
Healthy dogs: Fasting blood samples from 20 clinical
healthy staff- or student-owned dogs were collected.
Included were clinically healthy dogs of any breed and
sex, of a minimum age of one year and a minimum
weight of 10 kg to ensure that collected blood volume
was < 2% of the total blood volume. The dogs were
considered healthy based on absence of clinical signs of
illness, an unremarkable physical examination and
variables of a CBC, biochemistry profile, a routine
coagulation profile including APTT, PT, fibrinogen,
D-dimers, TEG, and a urinalysis within the respective
reference intervals (RI). Dogs with a history of receiv-
ing any medication during the preceding 2 weeks as
well as bitches in estrus were excluded.
Diseased dogs: Blood samples from 20 client-
owned dogs with disease conditions predisposing to
thrombosis were collected between February 2010 and
March 2011. Inclusion criteria for dogs with diseases
associated with thromboembolic disease as defined by
the literature9–20 were dogs of any breed and sexwith a
minimum age of one year and a minimum weight of
10 kg suffering from either (1) systemic inflammatory
conditions (eg, acute pancreatitis, hepatitis, pneumo-
nia, pyometra) resulting in systemic inflammatory
response syndrome (SIRS) and confirmed by the
combined results of the clinical examination (eg,
hyperthermia or hypothermia, tachycardia, tachyp-
nea), amoderate tomarked increase in the acute-phase
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protein C-reactive protein (CRP, RI 0–35 mg/L), and
neutrophilia or neutropenia; (2) protein-losing condi-
tions (eg, protein-losing enteropathy [PLE], protein-
losing nephropathy [PLN], vasculitis), based on results
of the clinical examination and hypoalbuminemia (RI
26–44 g/L), either alone or in combination with pan-
hypoproteinemia (total protein RI 57–82 g/L), in addi-
tion to a urine protein:creatinine (UPC) ratio of > 1 in
cases of PLN; (3) Diabetes mellitus, confirmed by
hyperglycemia, hyperfructosaminemia and glucosuria,
with or without ketonuria; (4) Hyperadrenocorticism
confirmed by the combined results of the clinical and
laboratory examinations (CBC, biochemistry profile,
urinalysis, ACTH response test, and/or low-dose dexa-
methasone suppression test); and (5) neoplasia, con-
firmed cytologically and/or histologically. Candidate
dogs were identified based on history, clinical exami-
nation, and the above-mentioned criteria at admit-
tance to the UHCA. All owners consented to their dogs
being included in the study. Blood samples for CBC,
biochemistry profile, a routine coagulation profile, and
TEG were collected before treatment was initiated.
Dogs with a history of medication with nonsteroidal
anti-inflammatory drugs, corticosteroids, and antico-
agulants during the preceding 2 weeks as well as
bitches in estruswere excluded.
Sampling
Healthy dogs were fasted 12 hours prior to blood collec-
tion. From diseased dogs, blood was collected at admit-
tance to the hospital. In both groups, bloodwas collected
by jugular venipuncture, by applying minimum stasis
and using a 21-gauge butterfly needle. Blood was col-
lected in the following order: one serum tube (5 mL,
Vacuette, Greiner Bio-One International AG,Kremsmu-
enster, Austria), followed by 5 citrated plastic tubes
(2.7 mL, 0.109 M, 3.2%; BD Vacutainer TM Plus Plastic
Citrate tube), followed by one EDTA tube (2 mL, Vacu-
ette, Greiner Bio-One International AG).
Routine hematology, biochemistry, and
coagulation tests
After sampling, citrate tubes were carefully inverted 5
times to ensure mixing of citrate and blood, in a 1:9
ratio. One randomly selected citrate tube was used for
the standard coagulation profile. Serum and citrate
tubes for biochemistry and coagulation profiles were
centrifuged at 4000g for 120 seconds, and serum and
plasma were separated and collected within 30 min-
utes of sampling. The CBC and biochemistry profile
were run within 2 hours of sampling. The CBC was
determined using an ADVIA 2120 automated hema-
tology analyzer (Siemens Health Care Diagnostics
Inc., Deerfield, IL, USA) and the blood smear was
evaluated by a clinical pathologist. The biochemistry
profile was analyzed using an ADVIA 1800 (Siemens
Health Care Diagnostics Inc.). A coagulation profile
was performed immediately or the plasma was stored
at 80°C until analysis. APTT (aPTT SynthAFax;
Instrumentation Laboratory, Bedford, MA 01730,
USA), PT (PT-Fibrinogen, Instrumentation Labora-
tory), and fibrinogen concentration (PT-Fibrinogen,
Instrumentation Laboratories) were measured using
the ACL TOP 500 analyzer (Instrumentation Labora-
tory). D-dimer concentration was measured with an
immunofiltration assay (D-dimer Single Test) on the
NycoCard READER II (Medinor A/S, Brøndby, Den-
mark) found to give accurate results for canine sam-
ples.32 A plasma pool from 10 healthy dogs was used
as a reference for plasma-based coagulations assays.
The plasma pool was stored at 80°C for no longer
than 6 months. The remaining citrate tubes were
stored in an upright position in a tube rack at room
temperature (20–25°C) for 30 minutes for subsequent
TEG analyses.
TEG analysis
Analyses using native, TF-activated, and kaolin-
activated assays, respectively, with or without t-PA
added, were performed using a computerized throm-
boelastograph (TEG 5000 Haemostasis Analyzer,
Haemonetics Corporation, Braintree, MA, USA).
Blood samples were analyzed in duplicate for healthy
dogs resulting in a total of 12 TEG analyses per animal.
For the diseased dogs, single measurements were
performed.
The analyses were performed using preheated re-
calcified TEG cups (37°C, 20 lL 0.2 M CaCl2) prior to
addition of citrated whole blood (WB). For native anal-
ysis, 340 lL citrated WB was added directly to the
cups. For the TF-activated samples, citrated whole
bloodwas activatedwith a solution of human recombi-
nant TF (Innovin, Siemens Healthcare Diagnostics,
Deerfield, IL, USA) at a final dilution of 1:50.000, as
previously described.32 Kaolin activation was initiated
by adding 1 mL citrated WB to kaolin-primed tubes
(Haemonetics Corporation), and 340 lL of this mix-
ture was added to the TEG cups. TEG analyses were
run for 120 minutes at 37°C. Six TEG parameters were
collected in the present study: the reaction time (R),
the clot formation time (K), the angle (a) representing
the kinetics of fibrin production and cross-linking, the
maximum amplitude (MA) reflecting the maximal clot
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strength, and the percent clot lysis detected at 30
minutes (Ly30) and 60 minutes (Ly60), respectively,
after MA is reached and representing the fibrinolytic
activity.
A pilot study was performed on WB samples from
healthy dogs with the addition of t-PA (Single-chain
recombinant tissue plasminogen activator 10 ng/lL,
Bionordika A/S, Glostrup, Denmark). A sample of 5 lL
t-PA was prediluted 1:10 in a 4-(2-hydroxyethyl)-1-
piperazine ethanesulfonic acid (HEPES) buffer with
2% bovine serum albumin (BSA). Samples of 2.5 lL,
5.0 lL, 7.5 lL, or 10 lL of the prediluted t-PA were
mixed with 430 lL HEPES-BSA. An aliquot of 25 lL
of this mixture was added to 400 lL citrated WB to
give increasing final concentrations of t-PA (3.4 pg/lL,
6.7 pg/ll, 10.0 pg/lL and 13.4 pg/lL) in a total assay
volume of 340 lL. Higher t-PA concentrations showed
higher inhibitory effect on clotting activity and more
rapid completion of fibrinolysis. A final concentration
of 10.0 pg/lL t-PA resulted in consistent and maximal
fibrinolysis without affecting TEG-parameters R, K, a,
andMAwhen compared with TEGwithout addition of
t-PA, and thus used for the study (data not shown).
For the TF-activated assay, 7.5 lL prediluted t-PA
was mixed with 430 lL diluted TF, and 25 lL of the
TF-t-PA mixture was added to 400 lL citrated WB.
340 lL of the TF-t-PA-WB mixture was added to the
TEG cups yielding a final TF:WB ratio of 1:50.000. For
the kaolin-activated assay, 7.5 lL prediluted t-PA was
mixed with 430 lL HEPES-BSA buffer, and 62.5 lL of
the prediluted t-PA was then mixed with the kaolin-
WB mixture. 340 lL of the kaolin-t-PA-WB mixture
Table 1. Basic data including fibrinogen, D-dimers, platelet counts, and hematocrit in 16 control dogs and 20 diseased dogs predisposed to
thrombosis.
Dog # Breed
Age
(years) Sex Clinical Status/Diagnosis
Fibrinogen
(g/L)
D-Dimer
(mg/L)
Platelets
(109/L)
Hematocrit
(%)
Controls
n = 16 Different breeds 1–7 7 F
5 FS
1 M
3MC
Clinically healthy Range 1–4 Range 0.0–0.5 Range 200–500 Range 39–59
Dogs suffering from diseases predisposing to thrombosis
1 German Shepherd 5 M Acute myocarditis 8.02 0.1 99 (Aggregates) 49
2 French Bulldog 1 M Obstructive foreign body
intestine
6.76 NA 323 58
3 Island Sheepdog 12 F Severe mastitis. SIRS 12.7 0.2 NA NA
4 Mixed breed NA F Severe inflammation paw.
SIRS
11.6 0.2 463 43
5 Australian Kelpie 9 F Pyometra. SIRS 3.84 0.8 394 45
6 Labrador Retriever 11 F Pyometra. SIRS 6.81 0.3 589 58
7 Labrador Retriever 4 F Acute mild pancreatitis 5.37 0.7 247 53
8 Mixed breed 6 F Pneumonitis. SIRS. 4.92–5.42 0.3 219 58
9 Basenji 12 M PLN 4.02 0.5 720 48
10 Bichon Havanais 3 M LPE. PLE NA NA 696 46
11 Boxer 8 MC Chronic LPE. PLE 9.14 0.2 309 52
12 Mixed breed 7 FS Chronic necrotizing
pancreatitis. Vasculitis.
SIRS.
4.39 0.7 285 40
13 Kleiner M€unsterl€ander 6 MC PLN. Renal amyloidosis 10.88 NA 240 32
14 German Shepherd 9 FS Splenic+hepatic
hemangiosarcoma
0.8 4.1 55 (Aggregates) 18.5
15 Cairn Terrier 12 FS Primary thrombocytosis NA 0.7 1206 37
16 English Bulldog 1 MC Leukemia 2.31 1.6 87 (No aggregates) 37
17 Cocker Spaniel 11 F Mammary carcinoma 3.22 NA 905 31
18 Bernese Mountain Dog 8 M Primary histiocytic
sarcoma
4.81 2.6 92 (No aggregates) 42
19 Danish-Swedish Farmdog 6 FS Diabetic ketosis 4.51 < 0.1 461 48
20 Labrador Retriever 6 M Hepatic cirrhosis. SIRS. 1.44 0.2 218 41
F indicates female, FS, female spayed, LPE, lymphocytic-plasmacytary enteritis, M, male, MC, male castrated, PLE, protein-losing enteropathy, PLN,
protein-losing nephropathy, SIRS, systemic inflammatory response syndrome, NA, not analyzed.
The bold numbers indicate values outside the reference range.
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was added to the TEG cups, yielding the final t-PA
concentration of 10 pg/uL in the cup.
Statistical analysis
Descriptive statistics were used to summarize dog char-
acteristics at UHCA admission as well as findings of the
clinical examination, CBCs, and serum biochemical
analyses for dogs with disease conditions predisposing to
thrombosis. GraphPad Prism 5 (GraphPad Software Inc.,
San Diego, CA, USA) was used for statistical analyses. To
determine distribution of the data, D’Agostino-Paerson
normality test was applied. For normally distributed
data, repeatedmeasures ANOVAwas used followed by a
Bonferroni multiple comparison posttest. For nonpara-
metric data, a Friedmann test was used followed by a
Dunns posttest. We used aMann–Whitney test for com-
parison of the 2 unmatched groups. Statistical signifi-
cance was set at P < .05. Coefficients of variation for the
3 types of assays were determined for the samples from
the healthy dogs, as theseweremeasured in duplicate.
Results
Gender, breed, age, individual final diagnosis, fibrino-
gen, D-dimer, platelet count, and HCT of all dogs are
listed in Table 1. The control group consisted of 5 male
(4 castrated males, 1 intact male) and 15 female dogs
(10 intact females, 5 spayed females) with a mean age
of 4.2 years (range 1.1–7.1 years). Of the 20 control
dogs that were initially recruited, 3 dogs were excluded
due to abnormal serum biochemistry results, and one
dog was excluded due to a urinary tract infection. In
one dog, the age was unknown. In another dog, hema-
tology results were missing. In 2 dogs, results of a rou-
tine coagulation profile were missing, and in another 2
dogs, D-dimers could not be analyzed due to lipemia.
Urinalysis was conducted as part of the diagnostic
procedure in 15 of the dogs. No sampled animals were
retrospectively excluded from the study.
Figure 1. After the addition of tissue-plasminogen activator, percent
clot lysis after 30 minutes (Ly30) was significantly lower in the diseased
dogs compared with healthy dogs in all 3 assays, indicating a decreased
fibrinolytic activity and potential predisposition to thrombosis. CK indi-
cates Kaolin-activated assay; CN, citrated native-activated assay, TF,
tissue-factor-activated assay. *** = P < .0001
Table 2. Results of 3 different thromboelastography assays without addition of tissue-plasminogen activator with blood from control dogs and
diseased dogs predisposed to thrombosis.
Control Dogs Diseased Dogs
CK CN TF CK CN TF
R (minutes) 5.1 (3.3–7.9)
(CV: 8.6%)
6.1 (3.9–11)
(CV: 29.8%)
5.3 (3.7–7.6)
(CV: 4.9%)
5 (3.3–7.7) 5.45 (4–11.9) 4.6 (3.1–8.7)
K (minutes) 1.9 (1.2–2.8)
(CV: 20.4%)
2.4 (1.7–7.7)
(CV: 31.2%)
1.7 (1.4–2.8)
(CV: 11.5%)
1.3 (0.8–5.5) 1.4 (1–5.8) 1.15 (0.8–6.5)
Angle (deg) 63.1 (45.6–71.9)
(CV: 5.5%)
54.1 (29.3–65.7)
(CV: 10.1%)
62.7 (52.9–70)
(CV: 3.8%)
69.9 (36.9–78.6) 64 (33.6–76.2) 71.7 (27.7–78.8)
MA (mm) 58.6 (48.5–66.7)
(CV: 7%)
56.9 (42.5–65.8)
(CV: 7%)
59 (48.8–67.6)
(CV: 2.3%)
71.9 (36.8–83.9) 69.8 (35.4–71.7) 73 (32.9–73.7)
Ly30 (%) 0 (0–5.7)
(CV: 133.7%)
0 (0–4.8)
(CV: 755.2%)
0 (0–6.7)
(CV: 147%)
0 (0–4.8) 0 (0–8.7) 0 (0–9.2)
Ly60 (%) 1.5 (0–14.3)
(CV: 74.6%)
0.8 (0–11)
(CV: 134.7%)
1.1 (0–12.8)
(CV: 67.4%)
1.5 (0–9.6) 0.8 (0–9.3) 0.7 (0–11.2)
Data are means (range) and CV in control dogs (duplicate assays).
CK indicates Kaolin-activated assay; CN, citrated native-activated assay, TF, tissue-factor-activated.
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Comparisons of Ly30 and Ly60 values before and
after addition of t-PA in both groups of dogs were per-
formed using Friedmann test and Dunn’s post hoc
tests. The Friedmann test showed highly significant
differences in both healthy and diseased dogs (all
P < .0001) when comparing the 3 different assays for
Ly30 and Ly60, respectively. Dunn’s post hoc test
showed that addition of t-PA significantly decreased
Ly30 and Ly60 measurements (all P < .05) in both
healthy and diseased dogs, regardless of assay type
(Figure 1).
There were no significant correlations between
fibrinogen, D-dimer, platelet count, hematocrit, and
lysis parameters Ly30 and Ly60 before or after addition
of t-PA (results not shown). TEG variables before and
after addition of t-PA in both groups are reported in
Tables 2 and 3. There were no significant differences in
lysis parameters among the 3 assays or between the 2
groups of dogs before addition of t-PA.
The results of theMann–Whitney test showed that
Ly30 and Ly60 were significantly different after addi-
tion of t-PA (all P < .05) between healthy and diseased
dogs, regardless of the assay, but with the highest sig-
nificance (P < .0001) in the native assay. Examples of
a t-PA-modified TF-activated TEG tracing from a clini-
cally healthy dog and a diseased dog with resistance to
fibrinolysis are shown in Figure 2.
Threshold values for Ly30 and Ly60 for all 3 assays
were defined as lysis values (%) below the lower end
of the range of the healthy control group. Depending
on the assay used, between 11 and 13 of the 20 dis-
eased dogs had Ly30 values below the ranges obtained
from running the t-PA assays in healthy dogs. For
Ly60, between 10 and 14 diseased dogs had values
below the lower end of the range of the healthy control
group depending on the assay.
CVA values were only obtained for healthy dogs
based on duplicate analyses and are reported in
Tables 2 and 3 before and after addition of t-PA, respec-
tively. CVA before addition of t-PA was lowest in the
TF-activated assays for all measured parameters except
Ly30 and highest in the native assays for all measured
parameters except MA. After addition of t-PA, the
kaolin-activated assays had the lowest analytical varia-
tion for all measured parameters except K andMA.
Discussion
The results of this study show that t-PA-modified TEG
is able to activate fibrinolysis in canine whole blood
from both healthy dogs and dogs with diseases known
to predispose to thrombosis. However, the diseased
dogs were significantly more resistant to t-PA-induced
fibrinolysis than the healthy control group.
The majority of dogs in the diseased group had
lysis values significantly below the values obtained
from healthy dogs. Although there was an overlap
between some of the dogs in the diseased group and
the healthy dogs, a substantial number of diseased dogs
were clearly resistant to activation of fibrinolysis, inde-
pendent of the assay used. Interestingly, dogs with
fibrinolytic activity below the lower range of healthy
dogs in all 3 assays after the addition of t-PA had all
been diagnosed with either a systemic inflammatory
condition or a protein-losing disorder. The lowest indi-
vidual lysis variables were observed in dogs with PLN,
necrotizing pancreatitis, SIRS and hepatic cirrhosis,
Table 3. Thromboelastography results with addition of tissue plasminogen activator with blood of healthy control dogs and diseased dogs predis-
posed for thrombosis.
Control Dogs Diseased Dogs
CK CN TF CK CN TF
R (minutes) 5.2 (3.9–6.7)
(CV: 3.9%)
6.3 (4.8–11.9)
(CV: 30.1%)
5.5 (3.7–8.1)
(CV: 7%)
4.15 (3.1–9.9) 5.5 (3.8–114.9) 4.3 (3.2–116.2)
K (minutes) 2.5 (1.3–5)
(CV: 23.9%)
3.7 (2.2–10.4)
(CV: 31.6%)
4.4 (2.1–12)
(CV: 15%)
1.3 (0.8–4.8) 1.5 (0.8–5.2) 1.2 (0.8–7.8)
Angle (deg) 58.3 (35.8–70.6)
(CV: 5%)
45.6 (18.3–59.2)
(CV: 10.1%)
41.3 (16.6–63.4)
(CV: 9.3%)
70.4 (49.1–78.4) 66.9 (27.4–77.9) 71.6 (28.2–77.5)
MA (mm) 49.8 (32.9–60.2)
(CV: 7.6%)
45.5 (9.7–54.7)
(CV: 7%)
35.5 (2.9–53)
(CV: 10.2%)
67 (9.9–73.6) 65.6 (25.8–71.5) 68.7 (18.4–74.0)
Ly30 (%) 45.7 (18.1–73.3)
(CV: 14%)
62.6 (27.7–88.3)
(CV: 115.1%)
66.2 (26–79.7)
(CV: 26.6%)
14 (0.1–92) 14 (0–65.7) 18.5 (0–79.9)
Ly60 (%) 73 (42.9–87.1)
(CV: 7.2%)
81.8 (58.4–93.7)
(CV: 43%)
83 (53.4–90.1)
(CV: 12.1%)
40.6 (3.7–95.4) 29.1 (1.3–82.8) 48.5 (3.1–90.1)
Data are means (range) with CV in control dogs (duplicate assays).
CK indicates Kaolin-activated assay; CN, citrated native-activated assay, TF, tissue-factor-activated.
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with SIRS due to pneumonitis, and mammary carci-
noma, respectively.
As the majority of dogs with decreased fibrinolytic
activity suffered from conditions associatedwith systemic
inflammation, inhibition of fibrinolysis secondary to
acute inflammation could be one of themajor reasons for
our findings. Acute inflammation activates systemic
coagulationbyTF-mediated thrombin generation, down-
regulation of physiological anticoagulant mechanisms,
and inhibition of fibrinolysis, resulting in enhanced fibrin
formation and impairedfibrin degradation.33
Sepsis has previously been associated with
reduced activity of endogenous anticoagulants in dogs,
suggesting an imbalance of hemostasis with a tendency
toward a procoagulant state in affected dogs.18 For
instance, significantly increased thrombin-activatable
fibrinolysis inhibitor (TAFI) activity was determined in
dogs with bacterial sepsis.34
A
B
Figure 2. Examples of tissue-plasminogen-modified (t-PA) tissue-factor-activated thromboelastography tracings from (A) a clinically healthy dog where
addition of 10.0 pg/lL t-PA resulted in a clearly visible activation of fibrinolysis; (B) from a diseased dog predisposed to thrombosis, where the resistance
to fibrinolytic activity in spite of addition of 10.0 pg/lL t-PA is clearly visible. R indicates reaction time in minutes, and represents the time span from initi-
ation until the first fibrin polymers are produced. The cut-off value is when the amplitude reaches 2 mm. K = clot formation time in minutes, measured
from the end of R until an amplitude of 20 mm is reached, representing the speed of clot formation. Α = angle in degrees, representing the kinetics of
fibrin production and cross-linking. MA = maximum amplitude reached in millimeters, reflecting the maximal clot strength. Ly30 = clot lysis in percent
at 30 minutes after MA is reached; Ly60:clot lysis in percent at 60 minutes after MA is reached.
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Hemostatic abnormalities consistent with systemic
hypercoagulability are common in dogs with PLE and
PLN.11,35 PLN was associated with an increased risk of
thromboembolism in 22.2% of dogs in a case series of
137 dogs.36 The mechanisms leading to hypercoagula-
bility and increased risk for thrombosis in dogs with
protein-losing conditions are multifactorial; one of the
proposed causes is enteric and renal loss of antithrom-
bin (AT) as dogs with PLE and PLN have decreased AT
levels.11,35AT deficiency could lead to an increased
amount of thrombin, resulting in hypercoagulability.11
Endothelial cell injury with secondary activation of
the coagulation cascade and urinary loss of fibrinolytic
and anticoagulant proteins are other possible causes.35
We used and compared 3 different TEG assays in
our study. For the native assay, recalcified citrated
whole blood was used without an activator, and as
such carrying a higher risk of analytical variation.32 In
our study, the native assay had the highest analytical
variation both with and without addition of t-PA. For
the TF-activated assay, we used human recombinant
TF as an activator to initiate coagulation through the
extrinsic pathway in a concentration validated ear-
lier.32 The TF-activated assay had the lowest CV values
without addition of t-PA. Activation with kaolin initi-
ates coagulation via the intrinsic pathway. The kaolin-
activated assay had the lowest analytical variation after
addition of t-PA. All 3 assays can be used for activation
of fibrinolysis with the addition of t-PA. However, the
results cannot be used interchangeably as the activated
assays produced the least variable and most reproduc-
ible results, while the unactivated citrated native assay
showed high analytical variation as seen in other
canine studies.11,32 A study of 3 different TEG assays
(native, TF, kaolin) on WB from clinically healthy cats
confirmed the native assay having the highest CV and
the kaolin assay having the lowest CV.37 In human
samples, a CV between 4% and 14% with no signifi-
cant differences between TF- and kaolin-activated TEG
assays was described.38 The large analytical variation
in the native assay compared with the activated assays
can be explained by the absence of a standardized
amount of activator as initiation of coagulation in the
native assay occurs spontaneously.37
As all TEG parameters were significantly affected
in all 3 assays by the addition of t-PA in the healthy
control group, standard TEG analyses cannot be
replaced by t-PA-modified TEG to evaluate individual
hemostatic abnormalities besides fibrinolysis.
A limitation of this study was the small number of
dogs with diseases predisposing to thrombosis. Further
evaluation of fibrinolysis should include a larger group
of dogs, with different disease categories to study and
compare the levels of t-PA-activated fibrinolysis and
their potential correlation with development of throm-
bosis. In addition, measurement of downregulators of
fibrinolysis may be useful in evaluating the cause for
the decreased fibrinolytic response in dogs with dis-
eases predisposing to thrombosis.
Addition of t-PA to TEG can be used as a tool for
the assessment of endogenous fibrinolytic potential in
healthy dogs and dogs with diseases associated with
thrombosis. Furthermore, many dogs suffering from
diseases associated with thrombosis are more resistant
to t-PA than healthy controls. Dogs with the highest
resistance to t-PA in the present study were either suf-
fering from systemic inflammation or a protein-losing
disease. Thus, t-PA-modified TEG may be a promising
tool for the detection of decreased endogenous fibrino-
lytic potential or resistance to fibrinolysis.
Activated TEG assays appear to be less variable and
more reproducible compared with the native assay in
this study and therefore, activated assays are recom-
mended for future studies.
The clinical consequences of decreased fibrinolytic
activity are currently not known. Further investigation
of decreased fibrinolytic activity in dogs may help elu-
cidate the complex pathophysiological mechanisms
leading to hemostatic dysfunction in disease and the
potential development of thrombosis in dogs.
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